VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value

Dirim, Ayhan; Haberal, Asuman Nihan; Gören, Mehmet Reşit; Tekin, Mehmet İlteriş; Peşkircioğlu, Levent; Demirhan, Beyhan; Özkardeş, Hakan

doi:10.1007/s11255-008-9362-7

Cited by 26 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some molecules markers, such as CAIX (carbonic anhydrase IX), VEGF (vascular endothelial growth factor), GRP78 (glucose-regulated protein 78), CD146 had been found to be a powerful marker for the prognosis of RCC [15,16,17,18]. Circulating cfDNA, a biomarker that is easily accessible and preferably noninvasive, has been shown to have diagnostic and prognostic potential in RCC [12,19].…”

Section: Discussionmentioning

confidence: 99%

Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma

Wan

Zhu

Jiang³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Background: Circulating cell-free DNA (cfDNA) mostly originates from tumors and its level correlates with treatment. We assessed whether the level of plasma cfDNA could help monitor recurrence after nephrectomy. Methods: This study included 92 patients with clear cell renal cell carcinoma (cRCC). Quantitative real-time PCR was used to measure the level of plasma cfDNA before and after nephrectomy. Results: The pretreatment level of plasma cfDNA in patients with metastatic cRCC (6.04 ± 0.72) was significantly higher than in those with localized cRCC (5.29 ± 0.53, p = 0.017) or controls (0.65 ± 0.29, p < 0.001). Of patients with localized cRCC, those with recurrence had a significantly higher plasma cfDNA level than those without (p = 0.024). The patients with a high plasma cfDNA level had a significantly higher recurrence rate than those with a low plasma cfDNA level before and after nephrectomy (p = 0.018). Conclusion: The level of plasma cfDNA may be useful as a tool to monitor patients during follow-up and guide further diagnostic work-up for the detection of recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma

Wan

Zhu

Jiang³

et al. 2013

Urol Int

View full text Add to dashboard Cite

show abstract

“…Thus, overexpression of PCNA may potentially influence cell-cycle progression and modulate the effectiveness of radiation and chemotherapy. After these experimental studies, many clinical studies on PCNA expression in malignant tumors, including breast cancer [10], esophageal squamous cell carcinoma [11], rectal cancer [12], hepatocellular carcinoma [13], laryngeal squamous cell carcinoma [14], renal cell carcinoma [15], ovarian cancer [16], as well as NSCLC [17,18], have been conducted. However, the clinical significance remains controversial in NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Prognostic impact of nm23‐H1 and PCNA expression in pathologic stage I non‐small cell lung cancer

Liu

Wang

et al. 2011

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…remaining 42 articles were reviewed, and of these 23 were excluded, the reasons for which are shown in Figure 1. Thus, 19 studies were included in the quantitative synthesis [10,[19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. Five of these studies [20,22,25,33,36] did not provide data (HR or Kaplan-Meier curve) to calculate the HR for OS, PFS, or DSS, and therefore could not be included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Five studies [19,24,26,28,34] either provided HR data or data from which the HR could be calculated, and were included in the analysis of OS. Relatively high heterogeneity was observed among the five studies, therefore, a random-effects model of analysis was used (Q statistic = 15.993, I 2 = 74.99%, p = 0.003).…”

Section: Vegf Tumor Expressionmentioning

confidence: 99%

The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis

Shen

Liu

et al. 2017

CIM

View full text Add to dashboard Cite

Objective: Vascular endothelial growth factor (VEGF) serum level or tumor expression may be prognostic in renal cell carcinoma (RCC). The purpose of this meta-analysis was to examine the prognostic value of serum VEGF level and tumor expression in patients with RCC.Methods: PubMed and EMBASE databases were searched until September 26, 2016. Prospective and retrospective studies of RCC patients that had VEGF levels measured were included. Outcome measures were overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS).Results: A total of 14 studies were included in the meta-analysis. In patients with RCC, elevated serum VEGF level was not associated with OS (pooled hazard ratio [HR] = 1.16; 95% confidence interval [CI]: 0.52 to 2.60; p = 0.716), but was associated with poor DSS (pooled HR = 4.22; 95% CI: 2.02 to 8.79; p < 0.001) and PFS (pooled HR = 1.50; 95% CI: 1.22 to 1.85; p < 0.001). Removal of one study, however, resulted in elevated serum level being associated with poorer OS. Tumor VEGF expression was not associated with OS (pooled HR = 1.48; 95% CI: 0.74 to 2.95; p = 0.263), but was associated with worse DSS (pooled HR = 1.83; 95% CI: 1.24 to 2.71; p = 0.003). Conclusion:In patients with RCC, elevated serum VEGF level is associated with worse OS, DSS, and PFS, while tumor expression is only associated with worse DSS. The number of studies, however, was limited and the results should be interpreted with caution.

show abstract

VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value

Abstract: It is obvious that prognostic factors such as VEGF, COX-2, and PCNA may vary depending on histological subtype. The level of expression of these factors together with histological subtype may provide valuable predictive information about the outcome of treatment.

Cited by 26 publications

References 35 publications

Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma

Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma

Prognostic impact of nm23‐H1 and PCNA expression in pathologic stage I non‐small cell lung cancer

The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis

Contact Info

Product

Resources

About